<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00227695</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 35/03</org_study_id>
    <secondary_id>SWS-SAKK-35/03</secondary_id>
    <secondary_id>EU-20520</secondary_id>
    <secondary_id>CDR0000443594</secondary_id>
    <nct_id>NCT00227695</nct_id>
  </id_info>
  <brief_title>Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Comparing Two Schedules of Rituximab Maintenance in Rituximab-Responding Patients With Untreated, Chemotherapy Resistant or Relapsed Follicular Lymphoma: A Randomized Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and&#xD;
      help kill them or carry cancer-killing substances to them. It is not yet known whether giving&#xD;
      rituximab over a short period of time is more effective than giving it over a long period of&#xD;
      time in treating follicular non-Hodgkin's lymphoma.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying rituximab to see how well it works when&#xD;
      given over a short period of time compared to when given over a long period of time in&#xD;
      treating patients with follicular non-Hodgkin's lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Compare the efficacy of induction therapy with rituximab followed by short- vs long-term&#xD;
           maintenance therapy with rituximab, in terms of event-free survival, in patients with&#xD;
           follicular non-Hodgkin's lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare the safety of these regimens in these patients.&#xD;
&#xD;
        -  Compare the pharmaeconomical aspects of these regimens in these patients.&#xD;
&#xD;
        -  Compare the evolution of immunologic competence in patients treated with these regimens.&#xD;
&#xD;
      OUTLINE: This is a randomized, multicenter study.&#xD;
&#xD;
        -  Induction therapy: Patients receive rituximab IV weekly in weeks 1-4 and undergo&#xD;
           restaging between weeks 11-13. Patients with stable disease or progressive disease are&#xD;
           taken off study. Patients achieving partial or complete response are stratified&#xD;
           according to prior treatment status (untreated* vs treated with or without anti-CD20&#xD;
           therapy), presence of bulky disease** at study entry (yes vs no), and participating&#xD;
           center. Patients are then randomized to 1 of 2 maintenance treatment arms.&#xD;
&#xD;
      NOTE: *Patients treated with radiotherapy only are considered as therapy-naïve.&#xD;
&#xD;
      NOTE: **Defined as a mass or lymph node conglomerate ≥ 5 cm diameter.&#xD;
&#xD;
        -  Maintenance therapy: Patients start maintenance therapy within 7 days of randomization.&#xD;
&#xD;
             -  Arm I: Patients receive rituximab IV every 2 months for 4 treatments.&#xD;
&#xD;
             -  Arm II: Patients receive rituximab IV every 2 months for up to 5 years in the&#xD;
                absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months until disease&#xD;
      progression or relapse and then annually for up to 10 years after randomization.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 270 patients will be accrued for this study within 3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 8, 2004</start_date>
  <completion_date type="Actual">December 19, 2017</completion_date>
  <primary_completion_date type="Actual">May 3, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>at 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions during and after maintenance treatment</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A: Rituximab every 2 months x4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab 375 mg/m2 every 2 months x4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Rituximab (5 years)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rituximab 375 mg/m2 every 2 months for 5 years or until PD, relapse or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
    <description>comparing two maintenance schedules of Rituximab</description>
    <arm_group_label>Arm A: Rituximab every 2 months x4</arm_group_label>
    <arm_group_label>Arm B: Rituximab (5 years)</arm_group_label>
    <other_name>MABTHERA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed follicular lymphoma&#xD;
&#xD;
               -  Grade 1, 2, 3a, or 3b disease by WHO staging system&#xD;
&#xD;
          -  CD20-positive by immunohistochemistry&#xD;
&#xD;
          -  Previously untreated disease OR meets 1 of the following criteria for response to&#xD;
             prior treatment:&#xD;
&#xD;
               -  Chemotherapy-resistant disease&#xD;
&#xD;
               -  Relapsed or progressive disease&#xD;
&#xD;
               -  Stable disease&#xD;
&#xD;
                    -  At least 12 weeks since prior systemic treatment&#xD;
&#xD;
          -  At least 1 bidimensionally measurable lesion ≥ 11 mm by CT scan or MRI&#xD;
&#xD;
          -  No transformation to high-grade lymphoma secondary to low-grade follicular lymphoma&#xD;
&#xD;
          -  No prior or current CNS disease (i.e., CNS lymphoma or lymphomatous meningosis) NOTE:&#xD;
             A new classification scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ.&#xD;
             The terminology of &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former&#xD;
             terminology of &quot;low&quot;, &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol&#xD;
             uses the former terminology.&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction ≥ 50% by echocardiography or MUGA&#xD;
&#xD;
        Immunologic&#xD;
&#xD;
          -  No acute or ongoing infection&#xD;
&#xD;
          -  No HIV infection&#xD;
&#xD;
          -  No active autoimmune disease&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 months after&#xD;
             completion of the study treatment&#xD;
&#xD;
          -  No uncontrolled diabetes mellitus&#xD;
&#xD;
          -  No other medical condition that would preclude study participation&#xD;
&#xD;
          -  No other malignancy except nonmelanoma skin cancer or adequately treated carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
          -  No other condition (e.g., geographic proximity) that would preclude study compliance&#xD;
             and follow-up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Radiotherapy&#xD;
&#xD;
          -  Prior rituximab allowed&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  More than 4 weeks since prior regular administration of corticosteroids&#xD;
&#xD;
               -  Dose equivalent to ≤ 20 mg/day prednisone allowed for conditions other than&#xD;
                  lymphoma or lymphoma-related symptoms&#xD;
&#xD;
          -  No concurrent corticosteroids for prevention or treatment of side effects except acute&#xD;
             life-threatening side effects&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Prior radiolabeled anti-CD20 therapy (administered alone or in combination with&#xD;
             cytostatic drugs) allowed provided patient has achieved partial or complete response&#xD;
             after the therapy&#xD;
&#xD;
               -  At least 12 months since prior anti-CD20 therapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 30 days since prior systemic tumor therapy&#xD;
&#xD;
          -  More than 30 days since prior participation in another clinical trial&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Taverna, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kantonsspital Münsterlingen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michele Ghielmini, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>IOSI - Ospedale San Giovanni, Bellinzona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Center - Institute of Hematology</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia IEO</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center Skopje</name>
      <address>
        <city>Skopje</city>
        <zip>1000</zip>
        <country>North Macedonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia</name>
      <address>
        <city>Belgrade</city>
        <zip>SCG-11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NOU - National Institute for Oncology</name>
      <address>
        <city>Bratislava</city>
        <zip>83310</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panorama Medical Centre</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sandton Oncology Centre</name>
      <address>
        <city>Johannesburg</city>
        <zip>2121</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>CH-5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Claraspital AG</name>
      <address>
        <city>Basel</city>
        <zip>CH-4016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>CH-4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breitenbach Praxis Dr. Haberthür</name>
      <address>
        <city>Breitenbach</city>
        <zip>4226</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Bruderholz</name>
      <address>
        <city>Bruderholz</city>
        <zip>CH-4101</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>CH-7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal Universitaire de Geneve</name>
      <address>
        <city>Geneva</city>
        <zip>CH-1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital</name>
      <address>
        <city>Liestal</city>
        <zip>CH-4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana</name>
      <address>
        <city>Lugano</city>
        <zip>CH-6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Pourtalès</name>
      <address>
        <city>Neuchâtel</city>
        <zip>2002</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SpitalSTS AG Simmental-Thun-Saanenland</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Hirslanden</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitaetsSpital Zuerich</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Italy</country>
    <country>North Macedonia</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Macedonia, The Former Yugoslav Republic of</country>
  </removed_countries>
  <results_reference>
    <citation>Taverna CJ, Baasi S, Hitz F, et al.: First results of long-term rituximab maintenance treatment in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03. [Abstract] J Clin Oncol 27 (Suppl 15): A-8534, 2009.</citation>
  </results_reference>
  <results_reference>
    <citation>First results of long term rituximab maintenance treatment in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03. F. Hitz, S. Bassi, C. Taverna, W. Mingrone, T. Pabst, L. Cevreska, A. Del Giglio, D.A. Vorobiof, M. Simcock, M. Ghielmini Haematologica (2009) 94: s2; abstract 0413</citation>
  </results_reference>
  <results_reference>
    <citation>First results of long term rituximab maintenance treatment in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03. C.J. Taverna, S. Bassi, F. Hitz, W. Mingrone, T. Pabst, L. Cevreska, A. del Giglio, D.A. Vorobiof, M. Simcock, M. Ghielmini J Clin Oncol (2009) 27: 15s supplement; abstract 8534</citation>
  </results_reference>
  <results_reference>
    <citation>Rituximab maintenance treatment for a maximum of 5 years in follicular lymphoma: safety analysis of the randomized phase III trial SAKK 35/03. C. J. Taverna, S. Bassi, F. Hitz, W. Mingrone, T. Pabst, L. Cevreska, A. del Giglio, D.A. Vorobiof, M. Simcock, M. Ghielmini Blood (2010) 116: ASH Annual Meeting abstracts; abstract 1802</citation>
  </results_reference>
  <results_reference>
    <citation>Taverna C, Martinelli G, Hitz F, Mingrone W, Pabst T, Cevreska L, Del Giglio A, Vanazzi A, Laszlo D, Raats J, Rauch D, Vorobiof DA, Lohri A, Biaggi Rudolf C, Rondeau S, Rusterholz C, Heijnen IA, Zucca E, Ghielmini M. Rituximab Maintenance for a Maximum of 5 Years After Single-Agent Rituximab Induction in Follicular Lymphoma: Results of the Randomized Controlled Phase III Trial SAKK 35/03. J Clin Oncol. 2016 Feb 10;34(5):495-500. doi: 10.1200/JCO.2015.61.3968. Epub 2015 Dec 28.</citation>
    <PMID>26712227</PMID>
  </results_reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2005</study_first_posted>
  <last_update_submitted>May 13, 2019</last_update_submitted>
  <last_update_submitted_qc>May 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

